Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine for prevention of relapse after long-term treatment of schizophrenia
2004-003340-22Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (3 arms), sponsored by Pfizer. Primary endpoint: Time to impending relapse. Started Sep 2005; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-003340-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003340-22.